Analysts expect 10x Genomics to report Q2 2026 revenue of $146.67 million and a consensus EPS loss of $0.23, with the stock’s current price of $47.27 trading significantly above the average analyst price target of $25.23.
Investors are primarily focused on the commercial trajectory of the Xenium platform and the upcoming H2 2026 launch of the high-scale Atera platform.
Recent performance has been characterized by double-digit growth in spatial consumables revenue, providing a critical buffer against sluggish instrument sales amid constrained capital budgets. Management’s efforts to streamline operating expenses and leverage AI-driven data partnerships are expected to be central themes in the company’s outlook for the remainder of the fiscal year.